A new indication
In addition to being used mainly for the treatment of prostate cancer, the three-month-formulation of triptorelin has been registered in many European countries to treat severe sexual deviation (e.g. paedophilia).
Timelines
- First national approval in Swededn in 2006
- Approved in 8 additional EU countries in 2007 (Mutual Recognition Procedure)
- Launched in EU in 2009
- Approval in Switzerland in 2009
